Thank you Chintu.
reflect solid diverse product Our driven and by our third performance consistent results financial quarter portfolio. increasingly
third specialty. in XX%, EBITDA of Versus gross growth up injectables, quarter, adjusted adjusted revenue of revenue EPS was adjusted prior of net was high period, as year areas reported down $X.XX. such while diluted the and biosimilars, of million, $XXX we EBITDA For X% to X% investments ongoing and the adjusted due million $XXX total margin
track We full year meet to XXXX are our guidance metrics. on
increase review each year now million QX million, business versus X% net me $X prior which starting $XXX of delivered the with of or an Let segment, revenue period. generics,
epinephrine driven products. our product Our our strong by and which launches in portfolio, Adrenaclick declines our results brand, were offset legacy injector new growth auto in injectable
to innovations to our while Our customers complex patients. benefits balanced pressures delivering continues diversified new perform portfolio substantial well price and products, as and increasingly
due Looking expect a generics two to QX, sequential factors. increase we revenue in to
Vasopressin. Zafemy benefit quarter full and the of First,
the recall was may the rating AB same time. Vasopressin QX was Zafemy launched around in resolved the of you middle As and
the Alymsys our look our expect and in we weeks. to launch will second launched Second, biosimilar October first biosimilar, next couple of in
fact Given this the already acceleration. of realized on approved in confident sequential products and we're sequential growth
of and year Moving loss the by was our of up million versus growth million offset revenue of spray $X bolstered prior $XX of in XX%. with period. million XX% was The exclusivity revenues X% and prescriptions X% or Rytary XX% consistent to are approximately account respectively. nasal being driven decline net up by Group, up At our decreased Rytary quarter, Specialty Unithroid for QX partially, with small total we very XX% strong up ZOMIG $XX pleased of growth Unithroid Specialty and the and year-to-date our
given QX, the and revenues year. were we a growth prior the force as year, prior due nature of In to of sequential business well Healthcare, profitability the the growth at expect of and albeit channel million, quarter. reflecting $XXX similar the compared to seasonality in this and business about Specialty revenue of in grew expansion XX% or increase normal the this Looking the $XX has net to distribution year of period, levels Rytary strength driving to Unithroid continue distribution as channel. been low the million the to QX we continued The fourth expect Healthcare
million million is of to QX XX% stability. mix of XXXX efficiencies. Moving gross with adjusted of was lower QX as product offset than P&L operating adjusted inflation reflecting points QX $X Compared XXXX were consistent prior margin $XXX EBITDA XXX down quarters basis lower to two gross and XXXX. the margin QX was
generate and a inflation will Our cash products support From we areas performance sales labor and of perspective, freight drive a as in cash. absorbing growth, new incremental lot substantial like of continued in well higher costs. flow future marketing reflects investments to that as
delivery. prior For the settlement cash times growth seven comparable legacy portion ER we're Opana will leveraging. and At regarding we EBITDA times. we From legal a leverage the balance QX XXXX $XXX year focused million we're perspective, year-to-date our million of compared the at ago to generated we our years a and period. $XXX were work five continue flow now same Three to on [ph] drive reduce time point million $XXX has will to substantial sheet and operating excluding at total levels. debt in the of net
revenue $XXX with EBITDA which unchanged digit the prior to remains top $XXX guidance our with EBITDA is of in billion year reflecting $X.XX XXXX of million year billion full the million. For line million, growth. $X.XX mid-single line to $XXX Adjusted adjusted
reminder, our of million drive incremental and about inflation. million growth year adjusted a include As $XX $XX EBITDA to expectations full of investments future
and Let factors QX. from me acceleration that sequential the turn to we drive summarize QX will expect
First, injectables. performance businesses line as previously across mentioned, and expect our top as key we products driven strong by Zafemy Rytary, Unithroid, such three
addition the new products long expense already such seen ramping ALYMSYS, the and Second, third, XXXX all like Vasopressin of as stable gross actions. margins multiple launches approved new operating year we've up. other with favorable And
beyond consistent continue to durable our XXXX, expect catalysts. we with profile Looking key financial four
million to years. expect will commercializing over biosimilars, have few this full we First, our at plus these XXXX, approximately which we them $XXX of we year, a of began next benefit in in QX year first peak the and launches,
are $XXX Second, year. injectables the same million last considerably at year-to-date $XX building million time revenues to at compared
on mention, investment fourth, XXXX. as growth. With launches. in the pleased financial with and strong a it product summary, have period portfolio and I'd growth like drive consistency Chintu Chirag. IPX In later sustainable entering performance product rich with we're Rytary made choices that, launch of Unithroid Third, to to the long-term we are our and new we of on pass to expected in continued to And
